

Market Applicability/Effective Date														
Market	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	N/A	N/A	N/A	X	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

\*FHK- Florida Healthy Kids

## Hyaluronan Injections

DRUG.00017

CG-DRUG-29

Override(s)	Approval Duration
Prior Authorization	<b>Single course:</b> Single injection or weekly injections (seven days apart) for three to five consecutive weeks

Medications	Comments
Euflexxa (sodium hyaluronate)	Preferred
Gelsyn-3 (sodium hyaluronate)	
*Supartz (sodium hyaluronate)	
Gel-One (Cross-linked Hyaluronate)	Non-Preferred
GenVisc 850 (hyaluronate sodium)	
Hyalgan (sodium hyaluronate)	
Hymovis (non-crosslink sodium hyaluronate)	
Monovisc (hyaluronan)	
Orthovisc (hyaluronan)	
Synvisc (hylan polymers)	
Synvisc-One (hylan polymers)	

\* Supartz products were discontinued by manufacturer as of 10/18/15. Utilization management clinical programs will remain active as claims can adjudicate up to 3 years after agent discontinuation.

### APPROVAL CRITERIA

An initial course of intra-articular injections of hyaluronan may be approved for the treatment of pain due to osteoarthritis of the knee when all of the following criteria are met:

- I. There is documentation\* of a diagnosis of osteoarthritis and there is no evidence of inflammatory arthritis (for example, rheumatoid arthritis); **AND**
- II. There is documentation\* that the pain interferes with functional activities (for example, ambulation, prolonged standing); **AND**
- III. There is documentation\* of failure to respond adequately to at least 3 months of conservative therapy which includes activity modification, home exercise, protective weight bearing, and analgesics (for example, acetaminophen or non-steroidal anti-inflammatory drugs [NSAIDs] or the individual is unable to tolerate conservative therapy because of adverse side effects; **AND**

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability/Effective Date														
Market	FL & FHK	FL MMA	FL LTC	GA	KS	KY	LA	MD	NJ	NV	NY	TN	TX	WA
Applicable	N/A	N/A	N/A	X	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

\*FHK- Florida Healthy Kids

- IV. There is no contraindications to the injections (for example, active joint infection, bleeding disorder)

A repeat course of intra-articular injections of hyaluronan may be approved for the treatment of pain due to osteoarthritis of the knee for individuals who meet all of the following criteria:

- I. The individual met all of the criteria for an initial course of treatment; **AND**
- II. Six (6) months, or more, have elapsed since the conclusion of prior treatment cycle; **AND**
- III. There is documentation\* that the prior course of treatment resulted in pain relief and improvement in functional status.

**OR**

A single course of intra-articular injections of hyaluronan **may be approved** for the treatment of pain due to reducing and non-reducing disc displacement disease of temporomandibular joint (TMJ) disorders. (A single course usually involves weekly injections (seven days apart) for three to five consecutive weeks).

*\*Documentation may include, but is not limited to chart notes, prescription claims, prescription receipts, and laboratory data.*

**May Not Be Approved:**

- I. The use of Intra-articular injections or hyaluronan may not be approved for treatment of pain due to osteoarthritis of the knee when the above criteria are not met and for all other knee conditions.
- II. Intra-articular injections of hyaluronan **may not be approved** for other musculoskeletal conditions of joints other than the knee, including but not limited to osteoarthritis of the ankle, shoulder or hip.

State Specific Mandates		
State Name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

**Key References:**

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2016. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed April 21, 2016.

DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2016; Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.